Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 3/20 | 0.53 |
| ▸ | CTSL | P07711 | 3/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28529323 | 0.86 | CTSV (0.50) | CTSVCTSLHTR1AADRA1DADRA1A | |
| SCHEMBL12151484 | 0.84 | HTR1A (0.59) | CTSVCTSLHTR1AADRA1DADRA1A | |
| SCHEMBL1319057 | 0.82 | MAPT (0.55) | MEN1KMT2AMAPTALDH1A1ABCB1 | |
| SCHEMBL7822540 | 0.81 | CTSV (0.53) | CTSVCTSLHTR1AADRA1DADRA1A | |
| SCHEMBL4883017 | 0.80 | HTR1A (0.55) | CTSVCTSLHTR1AADRA1DADRA1A | |
| SCHEMBL21815059 | 0.80 | HTR1A (0.54) | CTSVCTSLHTR1AADRA1DADRA1A | |
| SCHEMBL3275499 | 0.79 | RXRA (0.49) | CTSVCTSLMEN1KMT2ANPC1 | |
| SCHEMBL9315348 | 0.78 | MAPT (0.56) | CTSVCTSLHTR1AADRA1DADRA1A | |
| SCHEMBL9315352 | 0.78 | MAPT (0.56) | CTSVCTSLHTR1AADRA1DADRA1A | |
| SCHEMBL9315201 | 0.78 | HTR1A (0.47) | CTSVCTSLHTR1AADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280042-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | HENNEQUIN LAURENT FRANCOIS ANDRE | 2010-11-04 | — | — | US | disclosed |
| US-7696214-B2 | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB (SE) | 2010-04-13 | — | — | US | disclosed |
| US-7160891-B2 | Quinazoline derivatives for the treatment of T cell mediated diseases | ASTRAZENECA AB (SE) | 2007-01-09 | — | — | US | disclosed |
| US-20060258642-A1 | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB | 2006-11-16 | — | — | US | disclosed |
| US-7049438-B2 | Quinazoline derivatives for treatment of tumours | ASTRAZENECA AB (SE) | 2006-05-23 | — | — | US | disclosed |
| EP-1450808-B8 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-01-04 | — | — | EP | disclosed |
| EP-1450808-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| US-20050038050-A1 | Quinazoline derivatives for the treatment of t cell mediated diseases | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | US | disclosed |
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | ASTRAZENECA AB (SE) | 2004-10-28 | — | — | US | disclosed |
| EP-1450808-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | Astrazeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045395-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| WO-2001094341-A9 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2003-04-17 | — | — | WO | disclosed |
| EP-1292594-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | AstraZeneca AB (SE) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001094341-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258642-A1 | Quinazoline derivatives for the treatment of tumours | TPD52L2, NQO2, H1-5 | CTSV 670/4885CTSL 431/4885HTR1A 1124/4885 |
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | NQO2, TOP1, TPD52L2 | CTSV 555/4885CTSL 302/4885HTR1A 474/4885 |
| US-20050038050-A1 | Quinazoline derivatives for the treatment of t cell mediated diseases | CD4, HLA-DRB1, IFNG | CTSV 2194/4885CTSL 1495/4885HTR1A 1538/4885 |
| US-20100280042-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | TPD52L2, NQO2, H1-5 | CTSV 670/4885CTSL 431/4885HTR1A 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.